GNBT News and Press, Generex Biotechnology From 01/29/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM. Joseph Moscato, Generex President & Chief Executive Officer ...

Announcing the filing for a trademark for The Complete Vaccine™, Generex Biotechnology ([[GNBT]] +28.9%), says it has made significant progress in the li-Key-SARS-CoV-2 vaccine program.Generex's majority-owned public entity, NuGenerex Immuno-Oncology, has completed the T Cell assays an...

The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS) Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1)...

Memorandum of Understanding (MOU) signed by both parties Negotiating final contract terms Upfront payment on closing Licensing fees, expenses, and price per dose to be determined Bintai Kinden Corporation Berhad ( www.bintai.com.my ) is an investment holding company he...

Generex Biotechnology ([[GNBT]] +6.5%) has signed a licensing and development agreement with a consortium of partners in China to utilize the Ii-Key vaccine platform technology from Generex's subsidiary NuGenerex Immuno-Oncology, for developing a vaccine against the G4 EA H1N1 swine...

$2.5 million upfront for the Ii-Key-H1 vaccine from NuGenerex-Immuno-Oncology (NGIO) and to initiate epitope identification for Ii-Key vaccine development against the emerging swine flu in China G4EA H1N1 100% funding for manufacturing, development and commercial registration and appr...

$50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancer Deal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a $5 million upfront licensing fee, 100% funding for manufacturing, development and comm...

MIRAMAR, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update ...

Generex Biotechnology ([[GNBT]]) signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment Partnership, and Beijing Youfeng International Consulting for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China....